b
r
c
revers
vaccinolog
system
vaxign
use
identifi
select
subset
five
african
swine
fever
asf
antigen
success
purifi
human
embryon
kidney
hek
cell
produc
modifi
vaccinia
viru
ankara
mva
viral
vector
three
hekpurifi
antigen
three
mvavector
antigen
evalu
use
primeboost
immun
regimen
swine
safeti
immunogen
studi
antibodi
respons
detect
pig
follow
primeboost
immun
four
week
apart
antigen
notabl
sera
vaccine
posit
immunofluoresc
asfv
georgia
infect
primari
macrophag
although
mvavector
fail
induc
antibodi
respons
interferongamma
spot
form
cell
respons
three
antigen
detect
one
week
postboost
highest
spot
form
cell
respons
detect
pig
prime
boost
recombin
tcell
prolif
respons
also
detect
postboost
collect
result
first
demonstr
asfv
subunit
antigen
purifi
mammalian
cell
express
mva
vector
safe
induc
asfvspecif
antibodi
tcell
respons
follow
primeboost
immun
regimen
swine
african
swine
fever
asf
one
import
diseas
domest
pig
et
al
etiolog
agent
asf
viru
asfv
larg
complex
dna
arboviru
member
asfarvirida
famili
tulman
et
al
asfv
share
featur
poxvirus
includ
cytoplasm
genom
organ
gene
express
tulman
et
al
although
asfv
infect
gener
asymptomat
african
wild
suid
asfv
infect
domest
pig
usual
result
highli
contagi
hemorrhag
diseas
costard
et
al
pig
surviv
recov
initi
infect
may
becom
persist
infect
serv
viru
reservoir
area
diseas
endem
oie
outsid
african
contin
diseas
endem
madagascar
sardinia
intens
erad
program
follow
asfv
outbreak
portug
spain
south
america
caribbean
success
sinc
introduct
georgia
asfv
spread
rapidli
vast
area
western
southern
russia
ukrain
republ
belaru
costard
et
al
effect
treatment
vaccin
asf
thu
current
control
measur
reli
mainli
detect
elimin
infect
anim
et
al
studi
domest
pig
use
convent
vaccin
approach
inactiv
avirul
live
attenu
asf
virus
tissu
cultur
adapt
ration
gene
delet
report
vari
level
homolog
protect
howev
surviv
anim
shown
develop
subclin
diseas
thu
rais
possibl
vaccin
anim
becom
carrier
sanchezvizcaino
et
al
although
protect
immun
mechan
poorli
understood
cellular
immun
respons
particularli
tcell
oura
et
al
takamatsu
et
al
humor
respons
onisk
et
al
wardley
et
al
thought
import
role
host
protect
earli
vaccin
studi
test
sever
bcell
immunodomin
asfv
subunit
recombin
protein
ie
produc
use
either
baculoviru
dnabas
vaccin
yield
variabl
success
argilaguet
et
al
argilaguet
et
al
bardera
et
al
et
al
interestingli
immun
respons
elicit
dna
vaccin
variabl
depend
fusion
tag
ie
solubl
ha
ubiquitin
select
asfv
recombin
antigen
express
argilaguet
et
al
recent
studi
use
asfv
express
librari
contain
approxim
individu
plasmid
clone
exclud
demonstr
correl
protect
tcell
respons
lacasta
et
al
result
studi
show
asfv
genom
kb
contain
addit
antigen
protect
potenti
impli
identif
determin
would
enabl
advanc
develop
protect
subunit
vaccin
candid
end
appli
silico
bioinformat
tool
identifi
rank
asfv
open
read
frame
orf
possess
attribut
desir
select
vaccin
target
vaxign
first
webbas
vaccin
design
program
predict
vaccin
target
base
genom
sequenc
util
revers
vaccinolog
rv
strategi
et
al
use
entir
annot
protein
sequenc
genom
vaxign
identifi
open
read
frame
possess
high
probabl
good
vaccin
candid
base
protein
subcellular
locat
ii
transmembran
helic
iii
adhesin
probabl
iv
sequenc
ortholog
analysi
among
pathogen
strain
v
sequenc
exclus
genom
nonpathogen
strain
vi
epitop
bind
mhc
major
histocompat
complex
class
class
ii
vaxign
use
ration
design
experiment
vaccin
sever
intracellular
pathogen
includ
brucella
rickettsia
prowazekii
caro
gomez
et
al
gomez
et
al
success
use
predict
potenti
vaccin
target
uropathogen
escherichia
coli
et
al
streptococcu
agalactia
pereira
et
al
human
herp
simplex
virus
xiang
current
studi
vaxign
tool
use
analyz
asfv
annot
genom
use
georgia
strain
refer
genom
identifi
rank
open
read
frame
antigen
subsequ
recombin
express
five
asfv
gene
success
purifi
mammalian
cell
hek
human
embryon
kidney
cell
andor
mva
modifi
vaccinia
viru
ankara
recombin
antigen
express
system
subsequ
evalu
safeti
immunogen
swine
use
differ
primeboost
immun
regimen
yorkshir
barrow
weigh
kg
use
accord
usda
polici
supervis
texa
univers
institut
anim
care
use
committe
iacuc
pig
obtain
local
commerci
sourc
state
texa
depart
crimin
justic
wynn
unit
fm
road
west
huntsvil
tx
experiment
anim
work
approv
anim
use
protocol
review
approv
texa
univers
iacuc
permit
experi
perform
condit
pig
receiv
mvavector
asfv
antigen
condit
pig
receiv
hek
recombin
asfv
antigen
termin
experi
day
postimmun
pig
monitor
least
twice
daili
clinic
sign
document
local
system
advers
effect
throughout
postimmun
phase
anim
care
allevi
anim
suffer
provid
attend
veterinarian
pig
fed
antibioticfre
commerci
pig
ration
twice
daili
water
ad
libitum
end
studi
pig
euthanat
intraven
overdos
commerci
euthanasia
solut
beuthanasiad
special
sodium
pentobarbit
mgml
sodium
phenytoin
mgml
intervetmerck
anim
health
madison
nj
oscul
stethoscop
confirm
lack
heartbeat
total
asfv
genom
use
vaxign
analysi
five
genom
download
nation
center
biotechnolog
inform
refseq
databas
v
access
nc
benin
georgia
ourt
avirul
field
isol
seven
genom
sequenc
kindli
provid
dr
john
neilan
kenya
malawi
mkuzi
tengani
warmbath
warthog
sinc
annot
individu
gene
seven
genom
unavail
time
studi
gene
code
sequenc
genom
determin
use
glimmer
softwar
delcher
et
al
annot
protein
sequenc
use
input
vaxign
pipelin
analysi
use
georgia
strain
genom
chapman
et
al
seed
genom
protein
sequenc
georgia
genom
vaxign
calcul
predict
follow
five
featur
transmembran
domain
ii
adhesin
probabl
iii
sequenc
conserv
among
asfv
strain
epitop
bind
iv
mhc
class
v
mhc
class
ii
molecul
et
al
xiang
five
featur
select
analysi
base
follow
rational
presenc
transmembran
domain
suggest
possibl
virion
surfac
locat
adhesin
protein
suggest
critic
viru
attach
entri
expans
protect
divers
strain
requir
use
conserv
gene
among
differ
pathogen
asfv
strain
vaccin
candid
mhc
class
iii
epitop
predict
immun
determin
test
vaxign
vaxitop
method
epitop
predict
describ
previou
studi
et
al
xiang
sinc
limit
swine
leukocyt
antigen
sla
specif
epitop
avail
train
epitop
predict
function
vaxitop
human
leukocyt
antigen
hla
epitop
predict
method
vaxitop
use
predict
asfv
epitop
bind
swine
mhc
epitop
screen
hla
allel
use
six
supertyp
hla
class
allel
eight
supertyp
hla
class
ii
allel
report
previous
de
groot
et
al
approach
ration
base
report
swine
human
share
mani
similar
term
genet
physiolog
meuren
et
al
suenderhauf
parrott
human
mhc
swine
sla
complex
share
multipl
paralog
region
chardon
et
al
key
featur
mhc
gene
cluster
encod
class
class
ii
membraneanchor
glycoprotein
differ
structur
cellular
tissu
express
specif
origin
peptid
present
tcell
tcell
subset
activ
chardon
et
al
sla
class
antigen
constitut
express
surfac
nucleat
cell
present
peptid
deriv
nuclear
cytosol
protein
cytotox
tcell
also
interact
natur
killer
cell
prevent
nkmediat
cytotox
lunney
et
al
sla
class
ii
antigen
express
primarili
surfac
antigen
present
cell
macrophag
bcell
tcell
dendrit
cell
present
peptid
deriv
exogen
protein
helper
tcell
lunney
et
al
vaxign
score
featur
combin
use
weight
rank
strategi
conceiv
base
project
team
knowledg
factor
contribut
potenti
asf
protect
specif
follow
asfv
weight
rank
use
adhes
probabl
mhc
class
epitop
bind
mhc
class
ii
epitop
bind
transmembran
domain
sequenc
conserv
among
asfv
genom
analyz
highest
weight
assign
mhc
class
epitop
ii
epitop
predict
score
sinc
mhc
class
epitop
may
stimul
cytotox
tlymphocyt
activ
mhc
class
ii
epitop
may
stimul
helper
antibodi
activ
adhes
probabl
transmembran
predict
score
assign
weight
base
potenti
contribut
protein
topographi
virul
weight
rank
strategi
appli
calcul
singl
score
orf
georgia
genom
code
sequenc
select
candid
see
tabl
onlin
version
doi
http
submit
mammalian
codon
optim
use
blue
heron
biotech
codon
optim
tool
chemic
synthes
seattl
usa
sequenc
without
atg
gene
clone
kpni
bamhi
site
vector
invitrogen
catalog
carlsbad
usa
obtain
aasfv
construct
sequenceverifi
plasmid
transfect
hek
freestyl
cell
invitrogen
catalog
use
g
plasmid
per
cell
orbit
shaker
c
cell
harvest
lyse
protein
purifi
use
sequenti
affin
tag
ionexchang
chromatographi
protein
analyz
western
blot
use
asf
convalesc
serum
confirm
recombin
protein
express
aasfv
construct
use
templat
pcr
new
fragment
clone
secret
compet
mbp
fusion
previous
describ
baculoviru
shuttl
vector
brown
et
al
high
five
cell
seed
l
cellsml
l
fernbach
flask
infect
recombin
baculoviru
multipl
infect
moi
grown
c
h
recombin
protein
purifi
chromatographi
use
amylos
resin
metalaffin
size
exclus
column
subsequ
solubil
mm
sodium
phosphat
ph
mm
sodium
chlorid
glycerol
chap
dimethylammonio
final
storag
buffer
recombin
protein
analyz
western
blot
use
asf
convalesc
serum
confirm
protein
express
five
recombin
protein
ctype
lectin
v
use
evalu
tcell
respons
individu
aasfv
construct
bear
orf
use
templat
pcr
amplif
pcr
product
contain
end
bamhi
clone
site
prior
atg
codon
ecori
clone
site
follow
taa
codon
vaccinia
transcript
termin
sequenc
tttttct
pcramplifi
fragment
digest
bamhi
ecori
restrict
enzym
clone
plasmid
encod
dsred
fluoresc
protein
flank
sequenc
tk
locu
mva
genom
homolog
recombin
orf
express
strong
sel
earlyl
vaccinia
promot
viru
recombin
amplif
perform
cef
chicken
embryo
fibroblast
cell
accord
publish
procedur
staib
et
al
asfv
recombin
protein
express
sequenc
insert
dna
confirm
recombin
mvaasf
construct
twentytwo
pig
yorkshir
barrow
sourc
vaccin
intramuscularli
im
streptococcu
sui
autogen
vaccin
mvp
lab
omaha
ne
porcin
circoviru
circumv
pcv
type
tm
intervet
incmerck
anim
health
omaha
ne
day
age
addit
day
age
pig
receiv
intramuscular
vaccin
actinobacillu
pleuropneumonia
serotyp
bacterin
emulsivac
tm
mvp
lab
omaha
ne
porcin
circoviru
circumv
pcv
type
tm
intervet
incmerck
anim
health
omaha
ne
streptococcu
sui
autogen
vaccin
mvp
lab
omaha
ne
erysipelothrix
rhusiopathia
eryshield
tm
novarti
anim
health
inc
larchwood
ia
day
age
pig
vaccin
im
swine
influenza
flusur
xp
tm
zoeti
inc
kalamazoo
mi
porcin
reproduct
respiratori
syndrom
viru
fostera
prr
tm
zoeti
inc
kalamazoo
mi
actinobaccillu
pleuropneumonia
bordatella
brochiseptica
erysipelothrix
rhusiopathia
hemophilu
parasui
pasteurella
multocida
bacterin
parapleuro
shield
p
tm
elanco
inc
larchwood
ia
leptospira
canicola
l
grippotyphosa
l
hardjo
l
icterohaemorrhagia
l
pomona
bacterin
lepto
shield
tm
elanco
inc
larchwood
ia
vaccin
administ
accord
guidelin
intrast
swine
movement
pig
immun
im
antigen
outlin
tabl
day
experi
pig
day
age
weigh
kg
recombin
mvaasfv
construct
administ
im
tcid
tissu
cultur
infect
dose
ml
dose
tri
mm
ph
hekpurifi
recombin
asfv
antigen
administ
ml
cocktail
compris
gantigen
pb
phosphatebuff
salin
ph
adjuv
kindli
provid
merial
duluth
ga
proprietari
exclus
oil
water
anim
lipid
free
adjuv
abl
stimul
cell
mediat
immun
antibodi
detail
may
found
us
patent
number
merial
limit
duluth
ga
inject
site
tattoo
clinic
examin
daili
throughout
experi
peripher
blood
sampl
collect
day
preble
preboost
last
day
inlif
phase
immunolog
readout
pig
receiv
two
intramuscular
immun
day
interv
boost
match
antigen
site
euthan
day
postboost
id
identif
number
pig
studi
b
im
intramuscular
c
immun
site
left
atlant
drain
lymph
node
left
prescapular
drain
lymph
node
left
poplit
drain
lymph
node
right
atlant
drain
lymph
node
right
prescapular
drain
lymph
node
pb
use
site
inject
sinc
requir
amount
recombin
antigen
unavail
enzymelink
immunosorb
assay
elisa
use
evalu
asfv
antigenspecif
antibodi
pig
sera
briefli
elisa
plate
coat
l
ngl
ngl
ngl
dilut
mm
carbonatebicarbon
buffer
ph
incub
overnight
plate
wash
thrice
use
pbst
phosphatebuff
salin
tween
sigma
st
loui
usa
block
l
block
buffer
nonfat
milk
pb
ph
h
remov
subsequ
l
dilut
serum
block
buffer
immun
anim
ad
plate
incub
room
temperatur
h
plate
wash
thrice
pbst
l
block
buffer
horseradish
peroxidas
conjug
goat
antiporcin
igg
southern
biotech
birmingham
usa
ad
incub
room
temperatur
h
plate
wash
thrice
pbst
l
peroxidas
substrat
sureblu
reserv
tmb
tetramethylbenzidin
kpl
gaithersburg
usa
ad
incub
min
room
temperatur
l
tmb
stop
solut
kpl
ad
spectrophotometr
absorb
nm
measur
result
analyz
use
analysi
varianc
anova
signific
level
p
use
analys
teflonco
slide
well
electron
microscopi
scienc
hatfield
usa
incub
mgml
rattail
collagen
corn
new
york
usa
dilut
dulbecco
phosphat
buffer
salin
dpb
dulbecco
phosphatebuff
salin
invitrogen
min
c
ovendri
min
coat
slide
incub
overnight
biolog
safeti
cabinet
cm
uv
light
fresh
peripher
blood
mononuclear
cell
pbmc
enrich
macrophag
genovesi
et
al
rins
pb
three
day
postenrich
macrophag
detach
flask
mm
edta
ethylenediaminetetraacet
acid
centrifug
min
pellet
cell
suspend
complet
cultur
media
infect
multipl
infect
asfv
georgia
h
c
l
infect
mockinfect
cell
approxim
cell
place
well
precoat
teflon
slide
incub
overnight
c
slide
fix
chill
c
solut
compris
reagent
grade
aceton
methanol
min
store
c
use
ifa
evalu
dpb
base
block
solut
equin
sera
hyclon
lab
logan
usa
calf
sera
invitrogen
fetal
bovin
sera
hyclon
nonfat
dri
milk
carnat
markham
canada
bovin
serum
albumin
sigma
aldrich
ad
min
humidifi
chamber
c
serial
dilut
block
solut
serum
sampl
immun
control
pig
incub
infect
mockinfect
well
h
c
commerci
swine
sera
jackson
immunoresearch
west
grove
usa
use
neg
control
swine
serum
convalesc
anim
inocul
multipl
asfv
isol
kind
gift
e
j
kramer
plum
island
anim
diseas
center
use
posit
control
slide
rins
three
time
dpb
incub
goat
antiswin
sera
conjug
fluorescein
isothiocyan
fitc
kpl
min
c
slide
wash
three
time
dpb
mount
prolong
gold
antifad
reagent
dapi
invitrogen
olympu
immunofluoresc
microscop
model
olympu
digit
camera
model
dp
use
record
imag
ifa
perform
plum
island
anim
diseas
center
day
pbmc
isol
use
evalu
interferon
gamma
ifn
respons
recombin
asfv
antigen
gml
enzymelink
immunospot
assay
elispot
use
porcin
elispot
kit
mabtech
inc
cat
cincinnati
usa
elispot
readout
report
spot
form
cell
sfc
million
pbmc
hthymidin
incorpor
use
quantifi
tcell
prolifer
recombin
asfv
antigen
preand
postimmun
use
pbmc
previous
describ
njongmeta
et
al
briefli
prolifer
assay
conduct
use
pbmcswell
triplicatewel
plate
total
volum
l
complet
medium
contain
recombin
asfv
antigen
gml
cona
mitogen
gml
use
posit
control
wherea
cultur
media
serv
neg
control
recombin
maltos
bind
protein
mbp
use
gml
control
recombin
asfv
protein
express
mbpfusion
cell
cultur
h
c
label
ci
hthymidin
h
collect
use
autom
cell
harvest
tomtec
hamden
usa
incorpor
hthymidin
count
liquid
scintil
counter
incorpor
hthymidin
prolifer
bcell
present
mean
count
per
minut
cpm
triplic
well
elispot
prolifer
assay
readout
analyz
use
analysi
varianc
anova
follow
determin
fisher
least
signific
differ
distribut
assumpt
anova
met
kruskalw
test
nonparametr
equival
anova
anova
appropri
signific
level
p
use
analys
asfv
orf
weight
rank
use
vaxign
method
describ
method
section
vaxign
top
rank
orf
provid
tabl
onlin
version
doi
http
dxdoi
although
vaxign
rank
use
basi
select
vaccin
candid
antigen
final
candid
select
immunogen
evalu
swine
consid
addit
factor
gene
function
previous
report
antigen
immunogen
properti
particular
gene
base
consider
twelv
top
vaxign
rank
orf
two
previous
well
character
antigen
report
induct
neutral
antibodi
may
facilit
protect
immun
neilan
et
al
also
select
attempt
express
hek
cell
mva
viral
vector
see
tabl
onlin
version
doi
http
attempt
made
gener
fourteen
recombin
asfv
antigen
use
cell
transfect
plasmid
construct
encod
sequenceverifi
codonoptim
synthet
gene
seven
antigen
success
express
see
tabl
onlin
version
doi
http
troubleshoot
yield
differ
outcom
factor
respons
lack
express
antigen
cell
unknown
among
seven
asfv
construct
express
four
protein
success
purifi
demonstr
western
blot
see
supplement
fig
onlin
version
doi
http
suffici
quantiti
target
immun
dose
requir
swine
immunogen
studi
three
protein
contain
put
transmembran
domain
insolubl
triton
due
limit
fund
time
constraint
optim
protein
solubil
purif
pursu
ten
candid
see
tabl
onlin
version
doi
http
select
mva
construct
three
recombin
mvaasfv
construct
scale
success
demonstr
western
blot
supplement
fig
onlin
version
doi
http
suffici
quantiti
swine
immunogen
studi
optim
mva
construct
requir
remain
seven
candid
see
tabl
onlin
version
doi
http
dxdoiorg
sinc
result
recombin
mva
express
protein
unstabl
grow
cell
cultur
genet
instabl
observ
recombin
might
due
toxic
gene
product
mvainfect
fibroblast
sinc
addit
secretori
signal
tpa
human
tissu
plasminogen
activ
requir
success
gener
recombin
mvaasfv
virus
sinc
extend
time
optim
requir
success
gener
mva
construct
occur
complet
swine
immunogen
studi
construct
evalu
swine
immunogen
studi
fourteen
candid
also
select
express
baculoviru
protein
express
system
one
fourteen
candid
success
express
purifi
baculoviru
five
recombin
antigen
match
hek
mva
produc
antigen
use
swine
immun
use
reagent
tcell
respons
assay
final
subset
five
recombin
antigen
success
purifi
suffici
quantiti
util
test
evalu
swine
safeti
immunogen
studi
tabl
borca
et
al
b
galindo
et
al
et
al
four
antigen
exhibit
optim
vaxign
rank
rang
one
antigen
exhibit
low
rank
rang
vaxign
rank
maximum
minimum
none
intramuscularli
inject
test
articl
adjuv
control
prepar
induc
local
system
lesion
pig
one
inject
site
hekasfv
cm
encapsul
abscess
contain
white
inspiss
pu
necrot
debri
detect
postmortem
examin
day
abscess
cultur
posit
trueperella
pyogen
streptococcu
equisimili
streptococcu
porcinu
unrel
inject
site
observ
pig
first
two
week
experi
sinc
advers
tissu
reaction
granuloma
inject
site
subunit
protein
adjuv
mva
prepar
primari
booster
inject
febril
respons
vaccin
pig
either
vaccin
detect
result
indic
prepar
toxic
within
limit
clinic
paramet
evalu
induct
humor
respons
sera
test
anim
treatment
group
analyz
antigenspecif
antibodi
titer
elisa
igg
respons
detect
four
five
pig
day
postimmun
week
post
boost
fig
five
pig
immun
hekderiv
show
statist
signific
igg
respons
day
postimmun
compar
preimmun
preboost
sera
fig
specif
igg
respons
detect
sera
immun
pig
receiv
mvaasfv
prime
dose
confirm
elisa
result
sera
day
week
postboost
test
reactiv
georgia
macrophag
immunofluoresc
assay
ifa
fig
dilut
sera
pig
show
asfvspecif
igg
respons
wherea
sera
pig
adjuv
inject
neg
control
group
dilut
show
igg
respons
fig
consist
elisa
result
sera
anim
immun
recombin
mvaasfv
demonstr
detect
ifa
reactiv
igg
respons
borca
et
al
georgia
strain
genom
use
seed
genom
vaxign
rank
protein
base
predict
follow
featur
number
transmembran
helic
adhesin
likelihood
score
mhci
ii
epitop
score
sequenc
conserv
among
asfv
strain
rang
featur
score
unit
minimum
maximum
rang
vaxign
rank
maximum
minimum
correspond
total
number
identifi
orf
within
asfv
genom
baselin
preimmun
tcell
reactiv
baculovirusexpress
purifi
asfv
antigen
test
use
pbmc
prior
vaccin
background
reactiv
media
alon
rel
low
mitogen
posit
control
cona
work
expect
although
neg
control
maltos
bind
protein
mbp
use
asfvmbp
recombin
antigen
yield
high
background
count
may
due
prior
exposur
studi
anim
e
coli
pbmc
immun
swine
collect
day
use
elispot
tcell
prolifer
assay
tcell
respons
pig
prime
recombin
mvaasfv
boost
hekasfv
antigen
significantli
higher
p
compar
pig
prime
boost
mvaasfv
construct
mvasham
treat
pig
fig
one
pig
exhibit
strong
respons
one
week
postboost
howev
respons
wane
two
week
postboost
fig
signific
tcell
respons
either
one
two
week
postboost
pig
prime
boost
hekasfv
cocktail
fig
also
observ
hekasfv
antigen
test
overal
mbp
neg
control
tcell
respons
rel
high
may
mask
asfv
antigenspecif
respons
antigenspecif
tcell
prolifer
respons
detect
antigen
treatment
group
compar
neg
control
among
pig
prime
boost
hekasfv
antigen
pbmc
one
pig
exhibit
strong
respons
day
fig
howev
mean
pbmc
respons
statist
differ
mean
neg
control
treatment
fig
treatment
group
exhibit
statist
signific
p
respons
two
week
postboost
fig
respons
observ
two
week
postboost
fig
among
pig
prime
recombin
mvaasfv
boost
hekasfv
antigen
lymphocyt
pig
respond
day
respect
pig
respond
day
respect
pig
respond
day
fig
among
pig
prime
boost
recombin
mvaasfv
construct
pig
respond
day
respect
pig
respond
day
pig
respond
day
respect
fig
addit
pbmc
two
pig
immun
respond
adenovirusexpress
fig
demonstr
respons
two
differ
express
format
antigen
baculoviru
adenoviru
sinc
accident
introduct
almost
decad
ago
caucasu
region
subsequ
spread
eastern
russia
asfv
continu
pose
signific
risk
wild
domest
swine
popul
europ
asia
et
al
vaccin
develop
progress
hinder
gap
knowledg
antigen
effect
use
protect
prophylact
vaccin
asfv
rel
larg
genom
encod
protein
play
role
host
immun
respons
evas
dixon
et
al
date
inactiv
asfv
prepar
live
attenu
asfv
virus
bacteria
express
recombin
subunit
antigen
dna
vaccin
approach
met
limit
success
provid
consist
high
efficaci
homolog
heterolog
challeng
virul
asfv
bardera
et
al
jenson
et
al
ruizgonzalvo
et
al
order
help
identifi
potenti
new
asfv
antigen
target
recombin
antigen
deliveri
system
present
studi
silico
antigen
predict
program
vaxign
use
combin
two
differ
asfv
recombin
antigen
deliveri
system
mammalian
cell
modifi
vaccinia
ankara
vaxign
predict
antigen
protein
candid
silico
genom
sequenc
use
immunoinformat
algorithm
predict
tand
bcell
epitop
et
al
perform
comparison
informat
tool
report
et
al
xiang
vaxign
predict
relev
featur
util
publicli
avail
houseintern
develop
bioinformat
tool
exampl
vaxign
util
hmmtop
transmembran
helix
topolog
analysi
kall
et
al
spaan
adhes
probabl
predict
sachdeva
et
al
orthomcl
li
et
al
sequenc
conserv
analysi
mhc
class
class
ii
bind
epitop
predict
intern
develop
bioinformat
tool
vaxitop
use
et
al
xiang
vaxitop
program
base
posit
specif
score
matric
pssm
stormo
et
al
refin
cutoff
score
instead
percentag
top
number
vaxitop
util
statist
p
valu
determin
cutoff
valu
provid
high
sensit
specif
et
al
xiang
sinc
sla
epitop
knowledg
limit
hla
epitop
predict
method
predict
asfv
epitop
swine
mhc
class
employ
approxim
approach
employ
approach
justifi
high
degre
structur
similar
identif
crossspeci
influenza
viru
cytotox
lymphocyt
epitop
hla
sla
class
molecul
zhang
et
al
phylogenet
analys
demonstr
strong
sequenc
homolog
sla
hla
class
ii
gene
smith
et
al
previous
report
swine
epitop
predict
studi
burgaraestrella
et
al
et
al
zimic
et
al
recent
advanc
associ
swine
epitop
predict
report
fan
et
al
et
al
et
al
expand
immunoinformat
knowledg
improv
tool
may
result
better
predict
asfv
sla
epitop
futur
analysi
vaxign
rank
studi
base
method
assign
differ
weight
analysi
featur
weight
base
paramet
relat
potenti
immunogen
eg
weight
mhc
class
epitop
weight
adhes
probabl
transmembran
domain
presenc
sequenc
conserv
weight
assign
adhes
probabl
sinc
adhes
protein
may
surfac
attach
cell
fusion
protein
import
cell
invas
virul
sachdeva
et
al
exampl
spaan
use
vaxign
identifi
mani
spike
glycoprotein
human
coronaviru
adhesin
sachdeva
et
al
spike
protein
membran
compon
sever
acut
respiratori
syndrom
coronaviru
sarscov
identifi
critic
viral
pathogenesi
li
et
al
experiment
proven
effect
vaccin
candid
bisht
et
al
identifi
adhes
probabl
score
score
score
correl
previou
report
shown
protein
involv
asfv
hemadsorpt
ha
vitro
borca
et
al
borca
et
al
galindo
et
al
neilan
et
al
et
al
ruizgonzalvo
et
al
adhes
probabl
score
identifi
score
score
score
previous
report
potenti
protect
antigen
argilaguet
et
al
et
al
lokhandwala
et
al
neilan
et
al
weight
mhc
class
epitop
chosen
select
class
epitop
equal
maxim
immunogen
potenti
recent
report
correl
two
sla
irestrict
peptid
within
capabl
vitro
stimul
specif
secret
pbmc
challeng
survivor
pig
argilaguet
et
al
mhc
class
ii
score
rang
identifi
previous
report
potenti
protect
antigen
weight
assign
transmembran
domain
presenc
base
assumpt
transmembran
protein
would
surfac
virion
asfv
capsid
outer
layer
embed
onto
inner
membran
overal
vaxign
rank
previous
report
potenti
protect
antigen
follow
rank
rank
rank
rank
rank
three
previous
report
potenti
protect
antigen
rank
within
top
lower
rank
like
due
lack
predict
transmembran
domain
assign
weight
overal
rank
mani
top
vaxign
rank
antigen
includ
rank
antigen
previous
evalu
immunogen
studi
knowledg
studi
repres
first
report
strategi
weight
analysi
featur
antigen
rank
vaxign
swine
immunogen
result
obtain
present
studi
support
rank
approach
subsequ
use
select
asfv
recombin
antigen
induc
detect
immun
respons
twelv
top
vaxign
rank
candid
two
previous
character
antigen
chosen
attempt
recombin
protein
express
hek
mammalian
cell
mva
vector
system
mammalian
hek
express
system
select
base
hypothesi
authent
solubl
posttransl
modifi
recombin
asfv
protein
would
induc
humor
cellular
immun
respons
poxviru
mva
vector
system
select
base
demonstr
safeti
swine
abil
induc
vivo
express
one
specif
antigen
administ
host
moss
follow
vivo
administr
mva
infect
cell
express
recombin
antigen
de
novo
subsequ
process
proteasom
gener
peptid
present
cell
surfac
mhci
molecul
tcell
recognit
brewoo
et
al
present
antigen
peptid
profession
antigen
present
cell
via
mhc
class
pathway
induc
activ
tcell
featur
postul
desir
asfv
protect
addit
mva
vector
system
also
enabl
synthesi
longliv
antigen
stabl
protein
advantag
sinc
protein
immunogen
superior
effici
activ
immun
respons
vivo
furthermor
demonstr
tcell
respons
effici
activ
dendrit
cell
crosspres
stabl
mvaproduc
antigen
gasteig
et
al
reason
mva
system
fig
asfv
antigenspecif
pbmc
prolifer
follow
homolog
hekasfv
antigen
postboost
antigenspecif
pbmc
prolifer
respons
two
week
postboost
evalu
prolifer
assay
pbmc
prolifer
b
pbmc
prolifer
c
respons
detect
adjuv
neg
control
select
potenti
induct
asfvspecif
swine
immun
respons
express
purif
fourteen
select
antigen
mani
antigen
exhibit
highest
vaxign
score
prove
challeng
use
hek
mva
system
thu
limit
antigen
evalu
studi
previous
evalu
although
troubleshoot
perform
factor
contribut
lack
protein
express
hek
system
unknown
variou
physicochem
structur
featur
posttransl
modif
associ
target
protein
well
transcript
stabil
proteolysi
may
contribut
unsuccess
protein
express
three
protein
express
contain
put
transmembran
domain
insolubl
triton
technic
challeng
initi
observ
mva
systemgenet
instabl
lack
cell
growth
recombin
resolv
addit
secretori
signal
tpa
human
tissu
plasminogen
activ
enabl
success
gener
recombin
mvaasv
virus
inclus
secretori
tpa
signal
like
reduc
toxic
gene
product
allow
stabl
recombin
express
vaxign
rank
rank
rank
rank
rank
rank
rank
unfortun
recombin
success
construct
purifi
time
current
swine
immunogen
studi
could
evalu
futur
swine
immunogen
studi
five
antigen
success
purifi
suffici
quantiti
swine
safeti
immunogen
studi
tabl
exhibit
optim
vaxign
rank
rang
exhibit
low
rank
among
asfv
genom
analyz
five
gene
highli
conserv
mhc
hla
class
class
ii
score
greater
adhes
probabl
score
rang
except
four
gene
encod
least
one
transmembran
domain
one
encod
homologu
adhes
protein
rel
low
vaxign
rank
like
due
absenc
transmembran
domain
low
adhes
probabl
howev
major
compon
viru
capsom
account
approxim
onethird
viru
protein
mass
et
al
moreov
known
associ
membran
infect
cell
antibodi
block
asfv
entri
way
suggest
may
play
role
host
target
cell
attach
et
al
interestingli
highest
adhes
probabl
five
antigen
use
swine
immunogen
studi
demonstr
possess
neutral
activ
block
viru
attach
host
cell
target
et
al
despit
observ
protein
express
purif
challeng
antigen
rank
gener
vaxign
base
adhes
probabl
mhc
class
ii
epitop
bind
transmembran
domain
sequenc
conserv
among
asfv
strain
may
valuabl
futur
asf
vaccin
studi
aim
evalu
addit
antigen
asfv
candid
furthermor
difficulti
encount
express
highli
vaxign
rank
antigen
includ
addit
secretori
signal
may
provid
addit
knowledg
futur
asf
studi
attempt
evalu
implement
novel
antigen
deliveri
system
follow
homolog
hekasfv
antigen
primeboost
administr
evid
asfv
antigenspecif
antibodi
respons
clearli
demonstr
detect
igg
sera
collect
one
two
week
postboost
isotyp
switch
postboost
also
demonstr
elisa
ifa
data
given
recal
respons
asfv
antigenspecif
igg
respons
antibodi
respons
impli
induc
antibodi
neutral
asfv
confirm
administ
antigen
authent
contrast
pig
administ
mvaasfv
construct
cocktail
fail
gener
detect
asfv
antibodi
respons
outcom
somewhat
unexpect
sinc
express
system
elicit
antibodi
use
antigen
brewoo
et
al
anoth
viralvector
system
human
adenoviru
elicit
antibodi
use
antigen
lokhandwala
et
al
lack
antibodi
respons
may
relat
defect
antigen
present
eg
retent
mva
express
asfv
antigen
insid
infect
cell
may
limit
present
bcell
borrego
et
al
gang
et
al
use
molecular
element
tpa
enhanc
intracellularli
express
antigen
secret
bcell
recognit
mhc
ii
present
prime
helper
tcell
brewoo
et
al
embri
et
al
previous
report
sinc
administ
mvaasfv
construct
lack
secretori
tpa
signal
absenc
observ
antibodi
respons
may
due
limit
bcell
present
subsequ
result
report
herein
success
construct
seven
stabl
mvatpaasfv
viru
recombin
could
evalu
futur
swine
immunogen
studi
abil
induc
antibodi
tcell
respons
loperamadrid
unpublish
data
onset
asfv
antigen
specif
tcell
respons
demonstr
antigenspecif
cell
prolifer
cell
antigenspecif
tcell
prolifer
respons
detect
pbmc
homolog
hekasfv
antigen
primeboost
treatment
group
although
statist
signific
differ
mean
antigenspecif
tcell
prolifer
respons
detect
pmbc
mvaasfv
homolog
heterolog
primeboost
treatment
group
neg
control
antigenspecif
tcell
prolifer
respons
immun
antigen
observ
pbmc
individu
pig
treatment
group
fig
furthermor
asfv
antigen
specif
tcell
respons
detect
pbmc
mvaasfv
prime
hekasfv
antigen
boost
pig
result
congruenc
previou
report
emphas
import
heterolog
primeboost
regim
boyd
et
al
draper
et
al
pattacini
et
al
rattokim
et
al
correl
recent
relev
report
interestingli
antigenspecif
tcell
respons
also
observ
follow
adenoviralvector
homolog
primeboost
immun
strategi
lokhandwala
et
al
howev
note
correl
tcell
respons
host
protect
asfv
remain
unclear
least
context
use
live
attenu
asfv
model
carlson
et
al
current
studi
result
also
correl
recent
studi
use
asfv
interserotyp
v
ctype
lectin
recombin
chimer
virus
vaccinationchalleng
experi
swine
demonstr
partial
protect
defin
delay
timeto
death
day
onset
fever
onset
viraemia
partial
protect
like
due
host
respons
homolog
v
ctype
lectin
antigen
provid
evid
antigen
import
homolog
protect
immun
burmakina
et
al
burmakina
et
al
report
data
vaxign
rank
report
herein
support
potenti
role
v
rank
ctype
lectin
rank
protect
antigen
despit
absenc
humor
respons
follow
homolog
heterolog
mvaasfv
antigen
primeboost
administr
tcell
prolif
tcell
respons
detect
follow
hekasfv
antigen
boost
result
surpris
given
infect
host
target
cell
recombin
virus
result
endogen
antigen
express
antigen
present
context
mhc
molecul
result
activ
lymphocyt
rocha
et
al
although
detect
tcell
respons
impli
role
asf
protect
result
encourag
suggest
mva
vector
may
suitabl
platform
evalu
abil
confer
protect
recent
adenovirusvector
asfv
multiantigen
cocktail
express
polyprotein
antigen
demonstr
induc
antigenspecif
antibodi
tcell
respons
absenc
asfv
challeng
lokhandwala
et
al
antibodi
tcell
activ
report
adenovirusvector
asfv
multiantigen
cocktail
appear
robust
broader
compar
mvaasfv
primehekasf
antigen
boost
strategi
use
present
studi
one
possibl
explan
differ
time
interv
prime
boost
dose
may
critic
gener
optim
immun
respons
adenovirusvector
asfv
studi
time
interv
use
compar
week
interv
current
studi
protract
time
period
may
allow
induct
higher
number
antigenspecif
memori
cell
altern
two
differ
adjuv
system
use
adenovirusvector
studi
may
potent
adjuv
use
current
studi
lokhandwala
current
studi
use
differ
antigen
deliveri
system
demonstr
tcell
mediat
respons
may
contribut
asf
protect
previou
studi
demonstr
import
role
tcell
mediat
immun
host
protect
asfv
infect
one
studi
pig
immun
live
attenu
isol
protect
subsequ
challeng
virul
parent
isol
subsequ
deplet
cell
live
attenu
immun
swine
result
diseas
suscept
follow
virul
challeng
thu
demonstr
import
cellmedi
immun
protect
asfv
oura
et
al
anoth
studi
demonstr
experiment
dna
vaccin
compris
ubiquitin
tag
hemagglutinin
induc
antigenspecif
tcell
respons
confer
partial
protect
absenc
detect
asfv
antibodi
argilaguet
et
al
similarli
anoth
studi
use
baculovirusbas
mammalian
cell
express
fusion
hemagglutinin
protein
also
demonstr
partial
protect
correl
virusspecif
tcell
absenc
antibodi
followup
studi
identifi
addit
protect
tcell
determin
entir
asfv
genom
express
librari
lack
use
vaccin
result
vaccin
pig
protect
challeng
protect
correl
detect
specif
tcell
respons
absenc
detect
specif
antibodi
prior
challeng
lacasta
et
al
report
partial
protect
result
describ
previou
public
suggest
network
multipl
antigen
well
multipl
immun
mechan
involv
induct
asf
protect
like
previous
identifi
potenti
protect
antigen
yet
identifi
requir
complet
protect
combin
multipl
protect
antigen
optim
antigen
deliveri
adjuv
system
link
differ
immun
strategi
may
necessari
success
induc
humor
cellmedi
immun
confer
complet
protect
asf
vaccin
develop
significantli
hinder
knowledg
gap
asfv
antigen
associ
immun
mechan
respons
host
protect
report
demonstr
vaxign
silico
antigen
predict
program
use
tool
help
identifi
rank
potenti
antigen
featur
novel
asfv
protein
first
report
studi
appli
vaxign
tool
express
select
subset
five
asfv
antigen
mammalian
hek
well
mva
viral
vector
system
demonstr
safeti
antigen
swine
vaccin
hekpurifi
asfv
protein
promot
humor
immun
respons
detect
less
intens
cellular
immun
even
though
humor
immun
respons
induc
follow
mvaasfv
vaccin
cellular
immun
character
tcell
prolifer
produc
cell
observ
induc
tcell
respons
use
heterolog
mvaasfv
primehekasfv
antigen
boost
immun
regimen
support
rational
futur
studi
better
defin
respons
determin
correl
protect
subsequ
challeng
asfv
georgia
robust
tcell
bcell
asfv
immun
respons
consist
obtain
immun
swine
use
strategi
approach
primeboost
regimen
compris
best
asfv
antigen
use
futur
studi
evalu
asfv
vaccin
candid
abil
induc
durabl
protect
immun
virul
homolog
heterolog
asfv
challeng
author
declar
conflict
found
sponsor
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
